Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A modified Delphi consensus on tenosynovial giant cell tumour and giant cell tumour of bone : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM).

The bone & joint journal·2026
Same author

Childhood neurodevelopmental outcomes following hypertensive disorders of pregnancy.

Pregnancy hypertension·2026
Same author

Genome-Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

Nature medicine·2026
Same author

Genetic Diversity and Core Collection Construction of <i>Cymbidium ensifolium</i> var. susin.

Plants (Basel, Switzerland)·2026
Same author

Subjective cognitive decline among older adults and its link to diabetes, cardiovascular diseases, and other comorbidities: A US population-based study.

Journal of Alzheimer's disease : JAD·2026

Related Experiment Video

Updated: Jul 3, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Genetic aberrations in soft tissue leiomyosarcoma.

Jilong Yang1, Xiaoling Du, Kexin Chen

  • 1Department of Bone and Soft Tissue Tumor, Tianjin Cancer Hospital and Institute, Tianjin Medical University, Tianjin 30060, China.

Cancer Letters
|July 25, 2008
PubMed
Summary

Leiomyosarcoma, a smooth muscle tumor, often presents with complex genetic changes. Identifying these genetic alterations may reveal new targeted therapy options for this cancer.

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

Related Experiment Videos

Last Updated: Jul 3, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

Area of Science:

  • Oncology
  • Genetics
  • Pathology

Background:

  • Leiomyosarcoma is a malignant mesenchymal tumor originating from smooth muscle cells.
  • It commonly affects middle-aged/older adults and represents a significant portion of retroperitoneal, vascular, extremity, and uterine sarcomas.
  • These tumors are frequently characterized by complex karyotypes with substantial chromosomal gains and losses.

Purpose of the Study:

  • To explore the correlation between cytogenetic/molecular genetic aberrations and histopathologic features in leiomyosarcoma.
  • To identify specific oncogenes and tumor suppressor genes involved in leiomyosarcoma tumorigenesis.
  • To investigate the potential for targeted therapy based on identified genetic alterations.

Main Methods:

  • Karyotyping and molecular genetic analyses were performed on leiomyosarcoma samples.
  • Histopathologic features were assessed and correlated with genetic findings.
  • Analysis focused on identifying specific chromosomal aberrations, oncogenes, and tumor suppressor genes.

Main Results:

  • Leiomyosarcomas exhibit complex karyotypes with numerous chromosomal gains and losses.
  • Specific genetic aberrations were found to correlate with histopathologic characteristics.
  • The study identified key genetic alterations potentially driving leiomyosarcoma development.

Conclusions:

  • Understanding the genetic landscape of leiomyosarcoma is crucial for elucidating its tumorigenesis.
  • Identification of specific genetic targets offers potential for developing novel targeted therapies.
  • Further research into these genetic alterations may improve clinical outcomes for leiomyosarcoma patients.